Warberg Asset Management’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Warberg Asset Management’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-16,046	Closed	-$83K	–	254
2022 Q1	$83K	Buy	+16,046	New	+$63.9K	0.01%	137
2021 Q4	–	Sell	-27,000	Closed	-$130K	–	204
2021 Q3	$130K	Sell	27,000 -5,000	-16%	-$12.3K	0.02%	122
2021 Q2	$58K	Sell	32,000 -27,400	-46%	-$34.2K	0.01%	170
2021 Q1	$64K	Buy	+59,400	New	+$58.1K	0.02%	128

Other funds holding BCTXW

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Warberg Asset Management's BCTXW Position: Q2 2022 in Review

Warberg Asset Management sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q2 2022, closing a stake of 16,046 shares — an estimated $83K sold.

Warberg Asset Management first reported a position in BCTXW in Q1 2021 and held it in 4 quarters. The position peaked at $130K in Q3 2021. 7 funds tracked by Wall St. Rank hold BCTXW as of Q2 2022.

Warberg Asset Management reported no remaining BriaCell Therapeutics Corp Warrant position as of Q2 2022 after selling out during the quarter.
Warberg Asset Management sold 16,046 BriaCell Therapeutics Corp Warrant shares in Q2 2022, an estimated $83K.
Warberg Asset Management first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2021 and held it in 4 quarters.
Warberg Asset Management's BriaCell Therapeutics Corp Warrant position peaked at $130K in Q3 2021.
7 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q2 2022.

Based on Warberg Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.